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Background: The emergence of the role of microRNAs (miRNAs) in exacerbating drug resistance of tumours is
recently being highlighted as a crucial research ﬁeld for future clinical management of drug resistant tumours.
The purpose of this study was to identify dys-regulations in expression of individual and/or networks of miRNAs
that may have direct effect on neuroblastoma (NB) drug resistance.
Methods: Individual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant
to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the
parental and subcultured cell lines were analysed for miRNA expression proﬁling, using a high-throughput
quantitative polymerase chain reaction (RT-qPCR) miRNA proﬁling platform for a total of 668 miRNAs.
Results: A unique expression signature of miRNAs was found to be differentially expressed (higher than 2-fold
change) within all three NB chemoresistance models. Four miRNAs were upregulated in the subcultured
chemoresistant cell line. Three miRNAs were found to be downregulated in the chemoresistant cell lines for all
models.
Conclusions: Based on the initial miRNA ﬁndings, this study elucidates the dys-regulation of four miRNAs in
three separate NB chemoresistant cell line models, spanning two cell lines (SH-SY5Y and UKF-NB-3) and two
chemotherapeutic agents (doxorubicin and etoposide). These miRNAs may thus be possibly linked to
chemoresistance induction in NB. Such miRNAs are good candidates to be novel drug targets for future miRNA
based therapies against aggressive tumours that are not responding to conventional chemotherapy.
© 2015 Ayers et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural
Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Background
Undoubtedly, one of the most frequently occurring malignancies in
childhood is neuroblastoma (NB) [1], in most cases affecting children
under the age of ﬁve [2]. Neuroblastoma is a tumour that develops in
the embryonic stage [3] and derives fromprimordial cells of the sympa-
thetic nervous system known as neural crest cells [4]. These progenitor
cells cease to differentiate and mature, which is the natural course of
events in neural crest cells en-route to the development of the sympa-
thetic nervous system in the embryo [5]. The tumourigenesis from
these progenitor cells is thought to be due to the formation of self-
regenerating tumour stem cells that have the ability to produce a dis-
tinct range of different NB cell lineages according to their histology [6].
The clinicalmanifestations and degree of severity of NBmay behigh-
ly varied [7]. The initial phase of the condition is the presence of a pain-
less lump on the abdomen, neck or chest of the child [8]. However, the
tumour usually undergoes metastasis and the child consequently pre-
sents symptoms due to the NB tumour acting as a space-occupyingn behalf of the Research Network oflesion in the areas of the body that are affected. In order to aid clinicians
and oncologists to determine the severity of NB in the individual patient
and consequently implement more bespoke treatment strategies, an
International Neuroblastoma Staging System (INSS) [9] was devised,
based on the degree of NB metastasis and microscopic analysis of the
afﬂicted tissues of the patient. This staging system has proved to be of
immense value and is still presently being applied for neuroblastoma
diagnosis.
In overview, patients diagnosed with stage 1 or 2 NB conditions are
mainly subjected to surgery for excising the tumour mass, without the
use of chemotherapeutic cycles or other treatments [10]. However,
patients with stage 3 or 4 NB are at high risk and thus tumour de-
bulking/removal surgery is combined to other treatment strategies
such as chemotherapy (with or without bone marrow transplantation)
and low-dose radiotherapy [10].
Unfortunately, the emergence of chemoresistance within tumour
cells of solid tissues is one of the main reasons for treatment failure
and relapse in patients suffering frommetastatic cancer conditions [11].
Resistance of the tumour cell to chemotherapeutic agent exposure may
be innate, whereby the genetic characteristics of the tumour cells
are naturally resistant to chemotherapeutic drug exposure [12].Computational and Structural Biotechnology. This is an open access article under the CC BY
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a drug resistant phenotype over a deﬁned timeperiod of exposure of the
tumour cell tomultiple chemotherapy combinations [11,12]. Apart from
other biological and genetic factors inﬂuencing the chemoresistance
properties of such tumours, the role of non-coding RNAs such as micro
RNAs (miRNAs) [13,14] in the induction of such a phenotype is rapidly
being recognised [15–19].
Within the context of NB, there already exist links between miRNA
dysregulated expression patterns andNB clinical severity [20]. However,
scientiﬁc literature provides limited studies relating to the identiﬁcation
of miRNAs directly contributing to NB chemoresistance, with one of
them being miR-17-5p [21]. This study revealed that the exposure of
chemotherapy resistant NB murine tumour models to antagomirs for
miR-17-5p resulted in an increase in prognosis, due to enhanced apo-
ptosis and cell cycle arrest effects [21]. In addition, miR-21 is a known
oncomir and was found to be over-expressed in cisplatin resistant NB
cell lines [22]. Another study has also identiﬁedmiR-204 as a potentially
important miRNA that conveys suppressive properties against the
chemoresistance phenotype in NB [23].
2. Methodology
The purpose of this studywas to identify and validate (if any) specif-
ic miRNAs that could be directly involved in the exacerbation of
chemoresistance properties in NB cell lines. The utilisation of RT-qPCR
based miRNA proﬁling can nowadays be employed for serving such
research objectives.
2.1. Description of NB cell line chemoresistance models
Eight separate NB cell line models were implemented in this study.
Each model consisted of two cell lines, a parental chemosensitive to-
gether with a sub-cultured cell line that was rendered chemoresistant
to a single conventional chemotherapeutic agent through repeated
exposure (see Table 1).
2.2. Validation of chemosensitivity status for NB cell lines
Prior to miRNA proﬁling of all NB cell lines, validation of their
chemosensitivity status was paramount to ensure that the subcultured
chemoresistant cell line in eachmodel retained its drug resistance prop-
erties over several culturing passages without further drug exposure.
The method adopted for validating chemoresistance status in each
model consisted of luminescence-based cell viability analysis, through
the utilisation of the Cell Titer Glo assay [Promega, USA] on a Fluorostar
Optima luminescence plate reader platform [BMG, Germany], according
to the manufacturer's protocol. Due care was applied in maintaining a
seeding cell population across all culture wells utilised in the functional
assay, in order to avoid false positive viability readings.Table 1
List of NB chemoresistance cell linemodels. Subcultures of each parental
cell line were induced to acquire chemoresistance properties towards a
single chemotherapeutic agent. The SH-SY5Y and Kelly cell lines were
obtained from the Eggert group, Essen, Germany. The UKF-NB-3 cell
lines were obtained from the Cinatl Jr group, Frankfurt, Germany.
NB cell line Chemotherapeutic agent
SH-SY5Y Cisplatin
SH-SY5Y Doxorubicin
SH-SY5Y Etoposide
KELLY Cisplatin
KELLY Doxorubicin
KELLY Etoposide
UKF-NB-3 Doxorubicin
UKF-NB-3 Vincristine2.2.1. Cell culturing conditions and harvesting
The growthmediumutilised for culturing of all cell lines in this study
consisted of RPMI 1640 [Gibco, USA] treated with 10% foetal calf serum
[Gibco, USA] and 1% by volume of 1:1 penicillin/streptomycin mix
10,000 U/mL, kanamicin 10 mg/mL and L-glutamate 200 mM [Gibco,
USA] respectively. Prior to a three-minute step within T25 cell culturing
ﬂasks [Corning, USA], versene solution [Gibco, USA] was used for wash-
ing all adherent cells within the culture ﬂasks. The trypsin solution
utilised consisted of 0.05% trypsin with EDTA [Gibco, USA]. Harvesting
of cell suspensions for RNA extraction was performed by adding
0.7 mL Qiazol solution [Qiagen, Germany].2.2.2. NB chemoresistance model cell viability assay
For each chemoresistance model investigated in this study, both the
parental chemosensitive and subcultured chemoresistant NB cell lines
were grown in culture and simultaneously harvested and transferred
to a sterile 50 mL tube [BD Bioscience, USA]. The cell population density
for each cell linewas counted by extraction of a 20 μL sample (following
vigorous pipette mixing) and analysed on a Cellometer Auto T4 cell
counter platform [Nexcelom Bioscience, USA] according to
manufacturer's protocol. Both cell cultures where then diluted as neces-
sary with sufﬁcient growth medium to produce a cell culture with a cell
population density of approximately 10,000 cells/95 μL. Consequently,
95 μL aliquots from each cell line were transferred (following vigorous
pipette mixing) to an opaque Nunclon 96 well microtitre plate [Nunc,
USA].
For each cell line, 18 wells were utilised for consequent drug treat-
ment, and nine wells were to serve as non-treated NB negative controls
(NB cell culture only, with no drug exposure). A further six wells were
treated with 195 μL growth medium only, in order to act as negative
controls (drug exposure only). All remaining wells were treated with
200 μL growth medium. Finally, the microtitre plate was placed in an
incubator at 37 °C and 5% CO2 for 24 h, to allow cell adhesion on well
surface.
Following the 24-hour incubation, the microtitre plate containing
adherent cells was retrieved and treated with the appropriate chemo-
therapeutic agents for each chemoresistance cell line model. The vary-
ing drug dilutions (see Table 2) were prepared on the same day when
used for treatment, using ﬁlter sterilised water [Sigma, USA] within
the conﬁnes of a Class II laminar ﬂow cabinet. All light sensitive drug
dilutions were also covered in aluminium foil until required.
Once retrieved from the incubator, the plate was placed inside a
laminar ﬂow cabinet and all wells designated for treatment with the
appropriate chemotherapeutic agent were exposed. A 5 μL aliquot of
the appropriate drug and dose was pipetted, following vigorous pipette
mixing of the drug solution, into the appropriate triplicate wells. An
extra 5 μL aliquot of each drug dosewas applied to a single well contain-
ing only growth medium, in order to obtain background luminescence
data from a drug/growth medium solution for future use following
cell viability analysis. The plate was then re-incubated for a further 36 h.
Following this timeperiod, the platewas collected and a cell viability
assay was performed on all wells, by using the Cell Titer Glo assay
[Promega, USA] according to manufacturer's protocol.Table 2
Chemotherapeutic drug ranges utilised for investigating chemosensitivity status in each
cell line. All treatments were performed in triplicate for each drug dose.
Chemotherapeutic Drug dose range (ng/mL)
Plate row location Cisplatin Doxorubicin Etoposide Vincristine
B 50,000 28,999 1,000,000 4615
C 5000 2899.9 100,000 461.5
D 500 289.99 10,000 46.15
E 50 28.999 1000 4.615
F 5 2.9 100 0.465
G 0.5 0.29 10 0.046
Fig. 1. Results for cell viability analysis of Kelly NB chemoresistance models (n = 1, three
technical replicates/data point, SEMnot illustrated). In all three assays the chemosensitivity
status for each componentNB cell linewas not suitable for inclusion in themiRNA proﬁling
study (black — chemosensitive parental NB cell line; red — chemoresistant NB cell line).
309D. Ayers et al. / Computational and Structural Biotechnology Journal 13 (2015) 307–3192.2.3. Data analysis and statistical analysis
Following the assay, the Excel sheet containing all raw luminescence
data was collected for analysis, with outliers being identiﬁed and
discarded. The chemosensitivity proﬁles, based on the cell viability anal-
ysis data set results, were plotted by application of the Graph Pad Prism
software package [GraphPad Software Inc., USA]. No detailed statistical
analysis was performed on the resultant data sets as long as the
inhibiting concentration for 50% cell viability (IC50) demonstrated
distinct values, reﬂecting the chemosensitivity proﬁles.
2.3. NB cell line miRNA proﬁling
2.3.1. Cell line harvesting and lysis
All cell lines from each validated NB chemoresistance model were
cultured and harvested accordingly. Following trypsin incubation step,
each T25 ﬂask was subjected to horizontal mechanical shock, necessary
for dislodging all cells from the ﬂask surface. The resultant cell suspen-
sion from each ﬂask was transferred to an individually labelled, sterile
15 mL collection tube [BD Biosciences, USA] and centrifuged at
1500 rpm for ﬁve minutes to allow all cells to form a pellet at the base
of the collection tube. The supernatant from each collection tube was
aspirated by disposable, sterile glass pipette with due care to avoid
inadvertent aspiration of cell pellet. Consequently, the remaining cell
pellet was treated with 700 μL of Qiazol solution [Qiagen, Germany] in
order to induce cell lysis. This step was performed within the conﬁnes
of a fume cupboard and thorough pipette-mixingwas applied for ensur-
ing a resultant homogenous cell lysate suspension. Immediately after
cell lysis induction, all cell lysate suspensionswere snap frozen in liquid
nitrogen solution and transferred to a−80 °C freezer until RNA extrac-
tion was performed.
2.3.2. miRNA extraction procedure
All NB cell line lysates were allowed to thaw to room temperature
prior to miRNA extraction. Consequently, all lysates were treated with
the miRNeasy [Qiagen, Germany] miRNA extraction protocol, within
the conﬁnes of a fume cupboard. The resultant 30 μL volume of extract-
ed miRNA from each NB cell line lysate was quantiﬁed through
utilisation of the Nanodrop UV spectrophotometry platform [Nanodrop
Technologies, USA]. The extracted miRNA samples were then stored at
−80 °C until further use. The RNA quality was not tested following
extraction, as previous experience from earlier studies repeatedly
demonstrated that the RNA quality derived from NB cell lines was
always of an excellent nature (with RIN values above 9.0), thus such a
step was not performed.
2.3.3. RT-qPCR based miRNA proﬁling
All miRNA samples were allowed to thaw prior to further treat-
ments. The protocol utilised in this step was a validated, high through-
put RT-qPCR based miRNA proﬁling method [30]. In summary, miRNA
samples were diluted to a standardised concentration and initially sub-
jected to a megaplex reverse transcription protocol [30]. This was
followed by a pre-ampliﬁcation step and eventual qPCR analysis [30].
2.3.4. Data normalisation and analysis
All rawCqvalues obtained fromeach individual runwere corrected by
inter-run calibrators (ﬁve individual small nucleic RNA assays— RNU24,
RNU44, RNU48, RNU6B, U6 snRNA; two technical replicates/assay/plate)
and consequently normalised against the average Cq value obtained
from the total quantity of miRNAs assayed within the same run [27].
The normalised Cq expression data for each miRNA was compared be-
tween the constituent chemosensitive and chemoresistant cell lines for
each chemoresistancemodel. AllmiRNAs found to be dysregulatedwithin
the chemoresistant cell line, following the adoption of a +/− 2× linear
fold change cut-off value, were deemed to be putative chemoresistance
miRNAs within the individual chemoresistance model. This nominal
cut-off value is subjective and was deemed to be acceptable to attain alegitimate short list ofmiRNAs having a tangible expression dysregulation
proﬁle of sufﬁcientweight as to lead to anoverall shift in chemosensitivity
proﬁle (in this case, see Discussion section).
Ultimately, all miRNAs dysregulated in all three chemoresistance
models' miRNA shortlists were identiﬁed and selected for further
investigation.
2.3.5. Multiplex RT-qPCR for putative chemoresistance miRNAs
The putative miRNAs identiﬁed from miRNA proﬁling to be dysreg-
ulated in the chemoresistant cell lines were further analysed by multi-
plex RT-qPCR.
Taqman miRNA RT kit [ABI, USA] was utilised for the reverse tran-
scription step. Reverse transcriptase (RT) primers speciﬁc for the rele-
vant target miRNAs [ABI, USA] were diluted (5 nmol) with 250 μL
nuclease free water [Sigma, USA], and 10 μL aliquots from each individ-
ual primer solutionwere pooled in a 1.5mL Eppendorf tube. The primer
pool was then diluted with nuclease free water or concentrated by
vacuum centrifugation in order to obtain a ﬁnal volume equivalent to
20% of the total RT reaction volume utilised in this step. The RT reaction
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100 nM dNTPs, 4 μL MultiScribe reverse transcriptase [Applied
Biosystems, USA], 2 μL of 10×RT buffer, 0.25 μL RNase inhibitor [Applied
Biosystems, USA] and 0.65 μL nuclease free water. The total reaction
volume was then placed in a thermal cycler and subjected to 30 min
at a temperature of 16 °C, followed by 30 min at 42 °C, 1 s at 50 °C,
5 min at 85 °C and 5 min at 4 °C respectively. The ﬁnalised reaction
volume was diluted by a factor of ﬁve, prior to RT-qPCR step.
The TaqMan®miRNA assay for RT-qPCR quantiﬁcationwas utilised in
this step for all miRNA assays. Assays for hsa-mir-99b, hsa-mir-125a and
hsa-mir-425 were also prepared as reference miRNAs for post-run data
normalisation and analysis. All miRNA assays for each cell line sample
cDNA were performed in triplicate, with water — containing negative
controls. The reaction volume (perwell) contained 2.5 μL TaqManMaster
mix, 0.125 μL TaqMan miRNA probe and primers, 2 μL of sample cDNA
and 0.375 μL nuclease free water. The cycling protocol was run on the
ABI 7900HT qPCR platform [ABI, USA] and consisted of an initial holding
stage of 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s/60 °C
for 1 min, ending with a ﬁnal holding stage of 37 °C for 5 min. Following
the qPCR run, the data was exported and analysed, including statistical
analysis, on the qBasePlus software package [Biogazelle, Belgium].
3. Results
3.1. Validation of chemosensitivity status for NB cell lines
Prior to performing miRNA proﬁling for each individual cell line
within the varying NB chemoresistance models, it was essential to con-
ﬁrm the chemosensitivity proﬁles. Thiswas implemented by performing
a luminescence based cell viability assay, following a pre-determined
exposure period by the cell lines to the relevant chemotherapeuticFig. 2. Results for cell viability analysis of UKF-NB-3 NB chemoresistance models (two separat
chemoresistance model was included in the miRNA proﬁling study due to a 10-fold linear ch
doses a reproducible, artiﬁcial increase in cell viability was noticed within this NB chemoresi
the study due to incongruent chemosensitivity proﬁles for each constituent NB cell line (blackagent. However, the luminescence detection platform also required
preliminary analysis to conﬁrm optimum performance.
From the eight NB chemoresistance cell line models available, cell
viability analyses only conﬁrmed threemodels to still have the necessary
chemosensitvity proﬁles required for investigating miRNA expression
proﬁling (see Figs. 1–4). The three validated models (SH-SY5Y/ETOPO,
SH-SY5Y/DOXO, UKF-NB-3/DOXO) were analysed by two individual
cell viability assays to ensure chemosensitivity proﬁles.
Each NB chemoresistance cell line model was analysed to conﬁrm
chemosensitivity status of its constituent cell lines. The cell lines that
conﬁrmed chemosensitivity status were re-analysed with a second,
identical cell viability analysis in order to ascertain such status prior to
miRNA proﬁling.
Following the set of cell viability assays on each NB chemoresistance
model, only three out of the initial eight cell linemodels were conﬁrmed
to have maintained their chemosensitivity proﬁles, namely the SH-
SY5Y/DOXO, SH-SY5Y/ETOPOandUKF-NB-3/DOXONB chemoresistance
models. The extracted RNA from constituent cell lines, from each of the
three cell line models, were consequently eligible for miRNA proﬁling.
3.2. NB cell line miRNA proﬁling
The expression proﬁling of 668miRNAs for each constituent cell line
of the three validated and selected NB chemoresistance cell linemodels
demonstrated that approximately 50% of all miRNAs are expressed
above the 35 Cq value (see Figs. 5–7). Additionally, the expression
scatterplot proﬁles highlight that overall miRNA expression is cell line
dependent.
The results of the miRNA expression proﬁling revealed that a
putative chemoresistance signature expression of seven miRNAs was
present in all three NB chemoresistance cell line models (see Fig. 8).e runs, n = 1, three technical replicates/data point, SEM not illustrated). The doxorubicin
ange in the IC50 dose for both constitutive cell lines. However, at elevated doxorubicin
stance model. The UKF-NB-3/vincristine NB chemoresistance model was not included in
— chemosensitive parental NB cell line; red — chemoresistant NB cell line).
Fig. 3. Results for cell viability analysis of SH-SY5Y NB chemoresistance models (n = 1,
three technical replicates/data point, SEM not illustrated). The cisplatin chemoresistance
NB model was not included in the study due to lack of a suitable chemosensitivity proﬁle
by the predicted chemoresistant NB cell line component for this model.
Fig. 4. Cell viability analysis results (2nd run, n = 1, three technical replicates/data point,
SEM not illustrated) for re-conﬁrmation of chemosensitivity proﬁles for each constituent
NB cell line chemoresistance model.
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sion by multiplex RT-qPCR miRNA assay, prior to proceeding to
chemoresistance function validation assays.
All identiﬁedmiRNAs deemed to be involved in NB chemoresistance
were consequently eligible for downstream validation studies.
3.3. Multiplex RT-qPCR for putative chemoresistance miRNAs
Once the short list of putative chemoresistancemiRNAswas elucidat-
ed, it was deemed necessary to validate such ﬁndings by re-conﬁrming
the degree of dysregulated expression of each individual putative
miRNA.
Since themiRNA proﬁling step did not utilise technical replicates for
each individual miRNA RT-qPCR assay (one replicate/miRNA), it was
essential to re-conﬁrm the dysregulated expression status for each
individual putative NB chemoresistance miRNA within each constitu-
tive NB cell line of each chemoresistance model utilised in this study.
This was implemented by performing a secondary RT-qPCR assay,
with three technical replicates for each miRNA assay, in order to ascer-
tain the speciﬁc miRNA expression levels.
Following re-analysis of RNA from each of the three NB
chemoresistance models' cell line constituents by multiplex RT-qPCR
miRNA assay, only four out of the original seven-member putativechemoresistancemiRNA signaturewere pursued for functional validation
(see Figs. 9–15).
4. Discussion
Initial performance results of the luminescence reader platform
proved to be successful in achieving speciﬁcity of luminescence analysis,
with a standard deviation of approximately 1%. Additionally, the
dynamic range of the luminescence platformwas also deemed optimal,
with the lower endof the platform sensitivity spectrumdenoted at a cell
suspension density of 12,500 cells/mL.
From the eight NB chemoresistance cell line models at disposal
in-house, only three models (SH-SY5Y/ETOPO, SH-SY5Y/DOXO and
UKF-NB-3/DOXO) demonstrated distinct chemosensitivity proﬁles for
the constitutive cell lines.
Analysis of the three Kelly NB chemoresistance models highlighted
incongruencies in the chemosensitivity proﬁles of the component cell
lines and was therefore excluded from the study.
For the UKF-NB-3 chemoresistancemodels, the UKF-NB-3/vincristine
model was also excluded due to inability to conﬁrm the projected
chemosensitivity proﬁles for the two component cell lines, over two
separate cell viability assays post-vincristine exposure. However, the
UKF-NB-3/DOXO cell line reproducibly demonstrated to conﬁrm the
predicted chemosensitivity proﬁles, with the doxorubicin-resistant
component cell line proving to be resistant to the drug exposure dose
on comparisonwith the chemosensitive counterpart cell line by a factor
of ten, on comparing the doxorubicin doses required to induce 50%
decrease in cell viability. A peculiar observationwas also denoted with-
in the UKF-NB-3/DOXOmodel, in that at the elevated doxorubicin doses
the cell viability in both component cell lines seems enhanced. This
observation was found to be reproducible across two separate cell
viability assays and was solely noticed within this speciﬁc NB
chemoresistance model (UKF-NB-3 cell line exposed to doxorubicin).
Possible explanations for such an anomaly would be technical interfer-
ence with the luminescence assay, though the actual source thought to
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Fig. 5. Scatterplot ofmiRNA expression for SH-SY5Y/DOXO cell linemodel constituents. This highlights only themarginal variation in the percentage ofmiRNAs that are actually expressed
within the individual cell lines.
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transient transfection validation assays concerning the UKF-NB-3/
DOXO model, the doxorubicin dose range utilised had to be reduced
accordingly.
Analysis of the SH-SY5Y chemoresistance models revealed that the
SH-SY5Y/cisplatin NB model had lost its chemoresistance phenotype,
due to the observation of near-identical chemosensitivity proﬁles by
both components of the NB model and therefore was excluded from
the study. For the SH-SY5Y/DOXO and SH-SY5Y/ETOPO chemoresistance
models, both met the predicted chemosensitivity proﬁles required for
inclusion in the study, although it was also denoted that the SH-SY5Y/
DOXO chemoresistance model demonstrated to be more robust. This
was due to the enhanced chemoresistance properties highlighted by
the doxorubicin-resistant cell line model component, on comparison
with its etoposide-resistant counterpart cell line. Such phenotypes were
conﬁrmed for both NB chemoresistance models, following secondary
cell viability assays.
The utilisation of RT-qPCR technology in a high throughput manner
for the purpose of quantitatively analysing the miRnome in clinical and
scientiﬁc studies is, of late, a rapidly developing tool for investigating
miRNA expression. The essential reason for such popularity lies in the
fact that such a method combines the high-throughput efﬁciency of
the platform to simultaneously analyse almost 700miRNAs froma single
biological sample, though retaining the robustness and quantitative
analytical advantage of RT-qPCR techniques. Such a technique wasutilised in this study for identifying dysregulated expression of individual
and/or networks of miRNAs within the selected NB chemoresistance cell
line models.
Within the context of this study, pre-determined criteria were
applied for the purpose of identifying putative chemoresistance
miRNAs. All Cq values obtained for the investigated miRNAs, observed
at a value above 35, would lead to the interpretation that such miRNAs
were either not expressed at all, or expressed at very low levels in the
corresponding biological sample. This speciﬁc Cq threshold value was
thus utilised in order to eliminate false positive expression data inclu-
sion due to quantiﬁcation noise, which is normally introduced due to
natural biological variances or also due to the technical setup of the
RT-qPCR assay [24]. This is a ﬁne balance that was applied to ensure
that true ampliﬁcation read-outs for miRNAs expressed at a low level
(Cq value in the 30–35 range) would not be disregarded. Additionally,
a deﬁned threshold was applied for identifying which miRNAs in this
study were deemed as putative chemoresistance miRNAs. Only the
miRNAs that demonstrated linear fold change of above 2.0 (up-regulated)
and below 0.5 (down-regulated) in the chemoresistant cell line compo-
nent of each study model were included in the putative chemoresistance
miRNA shortlist, on comparison of the normalised Cq values for each
individual miRNA.
Such a fold change threshold range is deemed to bemore restrictive
as a selection strategy utilised for identifying relatively elevated levels of
dysregulated expression by the individual miRNA. It is important to
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minor miRNA dysregulations (ie. less than two fold up-regulation or
less than two-fold down-regulation) that may still prove to induce a
tangible phenotypic inﬂuence (eg. fold-change × 1.8).
However, the fold change thresholdwas implemented in this study at
such cut-off points for practical reasons, with the assumption that only
those miRNAs falling within the dysregulation thresholds were deemed
to have possible inﬂuence on NB cell line model chemoresistance
properties.
Consequently, it must be emphasised that the threshold fold-change
levels are entirely subjective and therefore a careful balance must be
attainedwhereby reliable hits can be selected, thoughwithout elevating
the stringency levels of the threshold fold-change values to the point at
which identiﬁcation of even a low quantity of hits would prove to be a
challenge. Since the minimummiRNA fold change acceptable for scien-
tiﬁc publications is a threshold of 1.5-fold, it would be recommended to
set the least stringent miRNA fold-change selection criteria at this level
(+/− 1.5 fold-change) for all studies of this nature [25–27].
The overview analysis of miRNA expression proﬁling of all three NB
chemoresistance models demonstrated that approximately 50% of the
miRNAs analysed in this study had a raw Cq value at/above a value of
35. ThosemiRNAshaving aCq value above the value of 35were expressed
at low/single molecule level and excluded from further analyses. The
notion that half of all miRNAs are expressed at low levels (or not
expressed) can be attributed to the fact that in most cancer conditionsthere exists an overall down-regulation of miRNA expression [28], with
the overall percentage of miRNAs being expressed in normal, tumour-
free tissues being higher than 50% (though such tissueswere not analysed
in this study).
In addition, the scatterplot analysis of normalised Cq values for each
individual miRNA, obtained from each constitutive NB model compo-
nent cell line, revealed overall low levels of data spreading. This implies
that only aminute fraction of the entiremiRnomemay be deemed to be
grossly dysregulated in such investigated cell line models.
For the three NB chemoresistance models investigated in this study
and following implementation of the above selection criteria, a total of
seven putative chemoresistance miRNAs were observed to be dysregu-
lated across all three NB models (see Fig. 8). From such a shortlist of
putative chemoresistance miRNAs, miR-188-5p demonstrated to have
reliable RT-qPCR, due to all miR-188-5p dysregulations across all three
NB chemoresistancemodels having Cq values below the 35.0 threshold.
For the remaining six putative miRNAs, such an observation was not
denoted from the RT-qPCR miRNA proﬁling analysis. This implies that
for such miRNAs, in one or more NB cell line model, the dysregulated
effect was deemed to be an ‘on/off’ effect, with the Cq value for the
individual miRNA from one of the two NB cell line model components
being above the pre-deﬁned 35.0 value.
Following miRNA expression proﬁling, it was necessary to conﬁrm
dysregulation of the selected putative chemoresistance miRNAs by
multiplex RT-qPCR techniques. This step was of importance for
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Fig. 7. Scatterplot of miRNA expression for UKF-NB-3/DOXO cell line model constituents. This highlights insigniﬁcant variation in the percentage of miRNAs that are actually expressed
within the individual cell lines.
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RT-qPCR assays were performed using one sole technical replicate for
each individual miRNA. Consequently, conﬁrmation by multiplex RT-
qPCR analysis utilising three technical replicates allowed for such vali-
dated putative chemoresistancemiRNAs to be further validated by func-
tional assay implementation.
Results from the multiplex RT-qPCR assays fully conﬁrmed the up-
regulated expression proﬁle for miR-188-5p across all three NB
chemoresistance models. Two additional putative miRNAs were also
of major interest, namely miR-125b-1# and miR-501-5p, due to conﬁr-
mation of dysregulated miRNA expression in at least two NB
chemoresistance models. The fourth putative miRNA was miR-204.
However, the down-regulated expression of miR-204 was only con-
ﬁrmed within the UKF-NB-3/DOXO chemoresistance model. This sug-
gests that, due to the mutated p53 status present in UKF-NB-3, this
dysregulation is cell line dependent and is totally absent in wild type
p53 status NB cell lines such as SH-SY5Y [29].
The remaining miRNAs failed to conﬁrm their dysregulated expres-
sion proﬁle within themajority (or all) of the three NB chemoresistance
models. Themain reasons for such results stems from theRT-qPCR tech-
nique implemented for miRNA proﬁling. A typical step utilised forsample preparation prior to miRNA proﬁling is the pre-ampliﬁcation
of RNA collected from the biological sample [30].
Therefore, any miRNAs identiﬁed as expressed following miRNA
proﬁling with a raw Cq value between 30 and 35 might eventually not
be equally identiﬁed on multiplex/singleplex RT-qPCR analysis, since
the latter is applied onnon-pre-ampliﬁedRNA samples solely. Ultimately,
such low expressed miRNA proﬁling expression values must be investi-
gatedwith due attention and awareness of such technical inﬂuences [30].
Following the results of this study, exact mechanistic links between
miRNAdys-regulation levels and chemoresistance phenotype cannot be
concluded. However, it certainly is of interest to highlight the possible
involvement of such miRNAs in affecting the most common means of
chemoresistance-inducing cellular pathways within such cell lines. A
typical example would be the effect of such miRNAs on the ABC trans-
porter systemand itsmember genes that regulate drug efﬂux properties
of the cell [36].
Such mechanistic links have been identiﬁed within other cancer
models. The study conducted by Ma and colleagues [37] demonstrated
the key roles playedbymiR-133a andmiR-326 in conferring adriamycin
chemoresistance properties to the HepG2 hepatocellular carcinoma
cell line model, through their regulatory effects on the ABCC1 gene.
Fig. 8.Graphsdemonstrating log-fold change inmiRNA expression for all three selectedNB chemoresistancemodels. ThismiRNA signature of sevenmiRNAswas identiﬁed as dysregulated
in the chemoresistant NB cell line components of all three selected NB chemoresistance models. miRNAs highlighted in green denote dysregulations in which both constituent cell lines
had a raw Cq value below the 35 cutoff value. This speciﬁc Cq threshold value was utilised in order to eliminate false positive expression data inclusion due to quantiﬁcation noise.
315D. Ayers et al. / Computational and Structural Biotechnology Journal 13 (2015) 307–319Furthermore, another study has highlighted the involvement of
miR-27b in sensitising liver and kidney carcinoma cells to conventional
cancer chemotherapies [38]. The study also demonstrated thatmiR-27b
exerts its drug sensitivity inﬂuences through the activation of p53-
dependent apoptotic pathways [38]. In colorectal cancer, miR-22 was
recognised to affect drug sensitivity properties to 5-ﬂuorouracil
treatments through its involvement in the regulation of autophagy
mechanisms, mainly due tomiR-22 direct action on B-cell translocation
gene 1 (BTG1) — a key molecular player in autophagy [39]. In gastric
carcinoma, miR-129-5p CpG island methylations were identiﬁed to
affect multi-drug resistance properties through targeted inﬂuences on
ABC transporter genes [40].
Future research focusing on the inﬂuence of miRNA effects on NB
chemoresistance properties may be highly varied and of equal impor-
tance. One speciﬁc research option would be to monitor the miRNA
expression proﬁle of individual NB cell lines during prolonged exposure
to speciﬁc conventional chemotherapeutic agents, until such cell linesdevelop sustainable chemoresistance properties. Such a study would
provide great insight onto which miRNA networks are most affected
by prolonged cytotoxic drug exposure, through evaluation of miRNA
proﬁles for dysregulated miRNA expression across the varying phases
of the drug exposure period. Consequently, the miRNA proﬁles across
the entire timeline for rendering a speciﬁc NB cell line chemoresistant
to individual or combinations of chemotherapeutic agents may provide
a wealth of information regarding which miRNAs could possibly have
key roles in orchestrating such a phenotypic shift at the cellular level.
Furthermore, the prospect of performing miRNA proﬁling of NB
cell lines having combinations of differing NB oncogene expression,
as described above, could also shed more light on the effect of NB on-
cogene expression on miRNA expression proﬁles. Downstream
miRNA dysregulations correlated to exacerbated oncogene expres-
sion may consequently be investigated for the identiﬁcation and
validation of key miRNAs deemed to act as intermediate effectors
of chemoresistance.
Fig. 9.Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-125b-1# following normalisation with reference miRNAs. Expected down-regulation of putative miRNA was con-
ﬁrmed in UKF-NB-3/DOXO and SH-SY5Y/DOXOmodels. Error bars represent standard deviation. Assays for hsa-mir-99b, hsa-mir-125a and hsa-mir-425 were also prepared as reference
miRNAs for post-run data normalisation and analysis.
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valuable use for enhanced mapping and characterisation of miRNA
networks with the capacity to interact and regulate complex gene
networks directly affecting the various biological processes within the
neuroblast that ultimately lead to the attainment of pronounced
chemoresistance properties [31].
Ideally, should any miRNA have be successfuly validated within
in vitro evaluations folowing our ﬁndings, further in vivo murine
model research could be enacted, consisting of NB xenograft implants
bearing constructs with individual putative chemoresistance miRNAs,
which are actively expressed on oral administration of tetracycline by
the individual mouse, thusminimising distress to the animal. FollowingFig. 10.Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-150 following normalisa
in all three chemoresistancemodels. Error bars represent standard deviation. Assays for hsa-mir
data normalisation and analysis.miRNA induced expression, the animals would be exposed to cytotoxic
agents and tumour progression is monitored accordingly. Induced
expression of the putative chemoresistance modulating miRNA would
be expected to lead to NB tumours having resilience to chemotherapy.
Clinical relevance of the identiﬁcation of individual/networks of
miRNAs directly linkedwithNB chemoresistance properties is two-fold.
Firstly, the identiﬁcation and proper validation of hallmark miRNAs
which are proven to be key players in conferring individual and/or
multi— drug chemoresistance properties to NB tumoursmay be utilised
for the development and implementation of novel diagnosticmiRNAex-
pression proﬁle and screens [32]. These screens may prove essential for
early recognition of NB tumours suspected to possess chemoresistancetionwith referencemiRNAs. Expected up-regulation of putativemiRNAwas not conﬁrmed
-99b, hsa-mir-125a and hsa-mir-425were also prepared as referencemiRNAs for post-run
Fig. 11.Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-188-5p following normalisationwith referencemiRNAs. Expected up-regulation of putativemiRNAwas conﬁrmed
in all three NB chemoresistance models. Error bars represent standard deviation. Assays for hsa-mir-99b, hsa-mir-125a and hsa-mir-425 were also prepared as reference miRNAs for
õpost-run data normalisation and analysis.
317D. Ayers et al. / Computational and Structural Biotechnology Journal 13 (2015) 307–319properties, thus giving the clinician an accurate picture of the clinical
manifestation in the individual child suffering from NB. Following
miRNA proﬁling and consequent functional assay validation techniques
described above, the results are still inconclusive regarding adopting the
seven-miRNA signature as hallmark biomarkers for NB chemoresistance.
The results from the RT-qPCR study of oncogene over-expression onMDR
gene dysregulation also proved to be inconclusive. Therefore, future
studies such as the experimental designs suggested for future research
described above might help to identify other miRNAs with more reliable
and robust validation assay results to conﬁrm their involvement in the
induction of NB chemoresistance properties. Such identiﬁed miRNAs
would ultimately be utilised in the clinical setting for diagnostic purposes
to recognise NB tumours having chemoresistance properties to conven-
tional chemotherapeutic agents.
Similar diagnostic screens have already been designed for accurate
diagnosis of other severe conditions such as human papilloma viral
infectious strains, though such bespoke microarray technology could
be implemented for the recognition of speciﬁc miRNA sequences
present in any clinical sample [33]. For NB diagnostic purposes,Fig. 12.Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-204 following normal
conﬁrmed in UKF-NB-3/DOXO NB model. Error bars represent standard deviation. Assays for h
post-run data normalisation and analysis.identiﬁcation of novel biomarkers may also be attained through the
proﬁling of other classes such as long non-coding RNA molecules
(utilising RT-qPCR), whole genome microarray proﬁling and also
exome next-generation sequencing.
However, the validation methods for conﬁrming individual candi-
date biomarkers may be time consuming. This is a particular problem
for exome sequencing approaches, due to the vast array of data that is
commonly generated and thus requires thorough bioinformatic analysis
prior to even identifying candidate exome sequence biomarkers for
consequent validation assays. In distinct contrast, the possibility of iden-
tifying novel body ﬂuid biomarkers, such as free-circulating miRNAs
[34], ultimately provides an extremely rapid diagnostic/prediction test
within the clinical setting due to the sole requirement of a blood sample
for RT-qPCR analysis. However, biomarker validation techniques
are very much dependant on the speciﬁc phenotype with which the
individual candidate biomarker needs to be reliably linked to (e.g.
chemoresistance, cell proliferation, cell differentiation).
For the validation of miRNAs associated with chemoresistance,
transient transfection of miRNA antagonists remains the mainstayisation with reference miRNAs. Expected down-regulation of putative miRNA was solely
sa-mir-99b, hsa-mir-125a and hsa-mir-425 were also prepared as reference miRNAs for
Fig. 13.Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-501-5p following normalisationwith referencemiRNAs. Expected up-regulation of putativemiRNAwas conﬁrmed
inUKF-NB-3/DOXO and SH-SY5Y/ETOPOmodels. Error bars represent standard deviation. Assays for hsa-mir-99b, hsa-mir-125a andhsa-mir-425were also prepared as referencemiRNAs
for post-run data normalisation and analysis.
318 D. Ayers et al. / Computational and Structural Biotechnology Journal 13 (2015) 307–319method due to the rapidity of the assay (72–96 h). Unfortunately, this
method also has the drawback that direct quantiﬁcation of candidate
biomarker miRNA by RT-qPCR cannot be performed, unless the
miRNA in question is known to down-regulate speciﬁc target genes
(which have been previously conﬁrmed in other studies).
Following the acquisition of additional information from these
novel biomarkers, the therapeutic avenues chosen by the clinician
will be decided with the inclusion of pre-emptive strategies against
chemoresistant tumours, based on the additional awareness of the
chemosensitivity status of the individual NB tumour. The therapeutic
options applied will thus maximise the chances of survival of the
patient, with minimal suffering due to chemotherapy-induced adverse
effects.
Secondly, suchmiRNAs are good candidates to be novel drug targets
for future RNAi based therapies against aggressive tumours that are not
responding to conventional chemotherapy [35]. These miRNA-directed
therapies are still in their infancy, though may in future prove to be a
novel molecular approach aimed at enhancing the efﬁcacy of conven-
tional chemotherapeutic treatments, with possible reduction in theFig. 14.Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-519b-3p following no
conﬁrmed for all three chemoresistancemodels. Error bars represent standard deviation. Assay
for post-run data normalisation and analysis.dose and frequency of chemotherapy cycles through which the child
has to undergo, ultimately reducing the level of distress and suffering
from chemotherapy-induced adverse effects.Acknowledgements
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